Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04066712 · ClinicalTrials.gov registry record · Phase 1

Renal PK Study of LC350189

A Phase 1 study, sponsored by LG Chem.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target

NCT04066712 is a Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 37 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04066712, a Phase 1 study, has completed, sponsored by LG Chem.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target

Study Summary

This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.

Interventions

  • DRUG LC350189 200 mg

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2019-11-19
Est. Completion 2020-09-12
Phase Phase 1

Sponsor

LG Chem

13 total trials

What the Registry Record Tells You About NCT04066712

The ClinicalTrials.gov registry entry for NCT04066712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which LC350189 200 mg is the first listed.

NCT04066712 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04066712 about?

NCT04066712 is a clinical study titled "Renal PK Study of LC350189". This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.

What is the current status of trial NCT04066712?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2019-11-19. Estimated completion is 2020-09-12.

What interventions are being tested in trial NCT04066712?

The interventions under investigation include: LC350189 200 mg (DRUG).

Who is sponsoring clinical trial NCT04066712?

This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.